Abstract: A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.

Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.

Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.

Abstract: A control agent comprising, as an active ingredient, a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline, azoxystrobin, picoxystrobin, pyraclostrobin, kresoxim-methyl, trifloxystrobin, metominostrobin, orysastrobin, famoxadone, fluoxastrobin, pyribencarb, cyazofamid, amisulbrom, flutolanil, mepronil, isofetamid, fluopyram, carboxin, thifluzamide, fluxapyroxad, furametpyr, penflufen, penthiopyrad, boscalid, diflumetorim, fluazinam, ferimzone, fenpyroximate, or an acid addition salt of any of these compounds shows an excellent controlling effect on Mesostigmata mites.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: Conditions necessary for antibodies to human PD-1 to have agonist activity are searched and an optimized agonist antibody is provided based on the conditions and used as a therapeutic for human inflammatory diseases. An agonist antibody to human PD-1 or a functional fragment thereof, wherein the antibody or a functional fragment thereof binds to domain #7 of human PD-1 as shown in SEQ ID NO: 9 is provided.

Abstract: A method for producing a compound represented by formula (1): or a salt thereof, comprising: a step B of producing a compound represented by formula (3): [in the formula (3), Boc represents a tert-butoxycarbonyl group] or a salt thereof by using a compound represented by formula (2): [in the formula (2), Ra represents a hydrogen atom or an optionally substituted arylmethyl group, Rb represents an optionally substituted alkyl or cyclic alkyl group, R3 represents a hydrogen atom, a halogen atom, or a thiazol-2-yl group, and Xa represents a hydrogen atom or a halogen atom] or a salt thereof; and a step C of producing the compound represented by the formula (1) or the salt thereof by using the compound represented by the formula (3) or the salt thereof.

Abstract: A bispecific antibody including a first domain which specifically binds to a mutant calreticulin protein and a second domain which specifically binds to a CD3 antigen. A pharmaceutical composition including the bispecific antibody or a functional fragment thereof. A diagnostic method for a myeloproliferative neoplasm, including detecting a polypeptide in a biological sample with the bispecific antibody.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: A novel use of agonist to PD-1 is developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition comprising an effective amount of a PD-1 agonist.

Abstract: Provided are crystals of 1-((2-(3,6-diazabicyclo[3.1.

Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.

Abstract: A control agent comprising, as an active ingredient, a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline, azoxystrobin, picoxystrobin, pyraclostrobin, kresoxim-methyl, trifloxystrobin, metominostrobin, orysastrobin, famoxadone, fluoxastrobin, pyribencarb, cyazofamid, amisulbrom, flutolanil, mepronil, isofetamid, fluopyram, carboxin, thifluzamide, fluxapyroxad, furametpyr, penflufen, penthiopyrad, boscalid, diflumetorim, fluazinam, ferimzone, fenpyroximate, or an acid addition salt of any of these compounds shows an excellent controlling effect on Mesostigmata mites.

Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.

Abstract: A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.

Abstract: [Problem] The present invention provides a method for producing and isolating a target quinolone derivative using general industrial facilities with high purity. [Solving means] The present invention also provides a method for producing a quinolone derivative, the method including reacting a ketone with an anthranilic acid derivative using an aluminum halide and removing the aluminum halide under basic conditions.

Abstract: A Mesostigmata mite control composition comprising, as active ingredients: a specific quinoline derivative compound such as 8-fluoro-2,3-dimethyl-6-(1,1-dimethylethyl)-4-(methylcarbonyl)oxyquinoline; and at least one of other pest control agents exhibits an excellent control effect on Mesostigmata mites.

Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Abstract: An aqueous suspension-form pesticidal composition comprising: at least one pesticidal active ingredient selected from the group consisting of amine derivatives represented by the following general formula (1) and salts thereof; a highly-purified and partially-desulfonated lignosulfonate; and an aqueous dispersion medium [In the general formula (1), Ar represents a pyridyl group optionally substituted with a halogen atom or the like, or a pyrimidyl group optionally substituted with a halogen atom or the like; R1 represents a hydrogen atom or a C1-6 alkyl group; Y represents a hydrogen atom or the like; and R2 represents a C1-6 alkyl group substituted with a halogen].